Xeltis

Jul 17, 2025

Xeltis announces positive data for Xabg, its coronary artery bypass conduit, in EU clinical trial

Jan 07, 2025

Xeltis announces completion of enrolment in EU Pivotal Trial for aXess and prepares for market approval

Nov 14, 2024

Xeltis announces FDA Breakthrough Device Designation for aXessTM and first patient treated in US pivotal trial

Nov 05, 2024

Xeltis expands leadership team with appointment of Luc Verhees as Vice President of Clinical Business Development

Jul 23, 2024

Xeltis appoints Shawn Gage as Vice President of US Clinical Affairs

Jun 13, 2024

Xeltis receives IDE approval from FDA for initiation of US pivotal trial for aXess(TM), its restorative vascular access conduit

Apr 17, 2024

Xeltis Announces Latest Results from aXess Trials to be Presented at 46th Annual Charing Cross Symposium